Compare Crispr Therapeutics AG (CRSP) vs Comfort Systems USA Inc (FIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Comfort Systems USA Inc — how do they compare? Crispr Therapeutics AG trades at $50.4 (market cap $4.97B), while Comfort Systems USA Inc trades at $1,700.79 (market cap $62.49B). The key difference: Comfort Systems USA Inc is far larger — about 12.6× Crispr Therapeutics AG's market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | FIX | |
|---|---|---|
Market Cap | $4.97B | $62.49B |
Sector | Health | Technology |
52-Week High | $76.78 | $2.07K |
52-Week Low | $44.34 | $532.14 |
Enterprise Value | $3.32B | $61.78B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Comfort Systems USA (FIX) trades at $1,732.03, down 1.37% on the day, amid a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations with Q1 2026 EPS of $10.51 versus $6.81 expected, driven by robust revenue growth and a 12.07% net income margin. Recent news highlights the company's expansion in modular capabilities and leadership in AI infrastructure demand, with a record backlog supporting future growth.
The stock presents a compelling growth story with strong earnings momentum and analyst consensus pointing to significant upside (price target $2,100), but faces risks from execution challenges on its record backlog and premium valuation multiples (P/E 51.24). Investors should weigh the company's solid cash flow generation and market position against technical weakness and high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →
